Marker Therapeutics (MRKR) FCF Margin (2016 - 2025)
Marker Therapeutics' (MRKR) quarterly FCF Margin came in at 172.2% in Q4 2025, up 3667.0% year-over-year from 4.57% in Q4 2024, and up 22.4% quarter-over-quarter from 221.9% in Q3 2025.
Powered by 
Analysis
Marker Therapeutics (MRKR) FCF Margin (2016 - 2025) Analysis & Trends
Marker Therapeutics (MRKR) has reported FCF Margin for 9 consecutive years, with 172.2% the latest figure, recorded in Q4 2025.
- On a quarterly basis, FCF Margin rose 3667.0% year-over-year to 172.2% in Q4 2025; TTM through Dec 2025 was 338.74%, a 19174.0% decrease from a year earlier, with the FY2025 full-year figure at 338.74%, down 17321.0% from the prior year.
- FCF Margin was 172.2% for Q4 2025 at Marker Therapeutics, up from 221.9% in the prior quarter.
- Over five years, FCF Margin peaked at 191.99% in Q2 2022 and troughed at 1575.39% in Q1 2025.
- A 4-year average of 445.45% and a median of 228.76% in 2022 frame the typical range for FCF Margin.
- Across the five-year window, FCF Margin soared 126809 bps in 2023 and sank 126695 bps in 2025, its largest moves.
- Over 4 years, FCF Margin stood at 228.76% in 2022, then plunged by 91 bps to 437.67% in 2023, then soared by 52 bps to 208.86% in 2024, then gained by 18 bps to 172.2% in 2025.
- The last three FCF Margin figures came in at 172.2% (Q4 2025), 221.9% (Q3 2025), and 218.11% (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | 59.74% |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | -826.50% |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | -66.71% |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | -3.46% |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | -497.31% |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | -13,981.63% |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | -33.11% |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | 48.98% |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | 18.67% |
| 10 | Marker Therapeutics | 23.37 Mn | 11.44 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -172.20% |
| Sep 30, 2025 | -221.90% |
| Jun 30, 2025 | -218.11% |
| Mar 31, 2025 | -1,575.39% |
| Dec 31, 2024 | -208.86% |
| Sep 30, 2024 | 62.17% |
| Jun 30, 2024 | -178.38% |
| Mar 31, 2024 | -308.43% |
| Sep 30, 2023 | -437.67% |
| Jun 30, 2023 | -864.10% |
| Mar 31, 2023 | -241.21% |
| Dec 31, 2022 | -228.76% |
| Sep 30, 2022 | -771.54% |
| Jun 30, 2022 | 191.99% |
| Mar 31, 2022 | -1,509.31% |
| Dec 31, 2020 | -14,419.92% |
| Jun 30, 2020 | -1,463.56% |
| Dec 31, 2019 | -2,139.30% |
| Jun 30, 2018 | -1,164.70% |
| Sep 30, 2017 | -1,106.36% |